EGFR and non-small cell squamous lung carcinoma: In 2015, guidelines recommended the evaluation of only two molecular markers: epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions, in patients with non-squamous non-small cell lung cancer.